Development of a cancer metastasis-on-chip assay for high throughput drug screening
Metastasis is the cause of most triple-negative breast cancer deaths, yet anti-metastatic therapeutics remain limited. To develop new therapeutics to prevent metastasis, pathophysiologically relevant assays that recapitulate tumor microenvironment is essential for disease modeling and drug discovery...
Main Authors: | Lutfiye Yildiz Ozer, Hend Salah Fayed, Johan Ericsson, Ayman Al Haj Zen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1269376/full |
Similar Items
-
Breast Cancer Cell Re-Dissemination from Lung Metastases—A Mechanism for Enhancing Metastatic Burden
by: Lucia Borriello, et al.
Published: (2021-05-01) -
Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment
by: Perelmuter VM, et al.
Published: (2019-07-01) -
Cancer-on-a-Chip: Models for Studying Metastasis
by: Xiaojun Zhang, et al.
Published: (2022-01-01) -
Biomimetic on-chip assay reveals the anti-metastatic potential of a novel thienopyrimidine compound in triple-negative breast cancer cell lines
by: Indira Sigdel, et al.
Published: (2023-09-01) -
A Novel High Content Angiogenesis Assay Reveals That Lacidipine, L-Type Calcium Channel Blocker, Induces In Vitro Vascular Lumen Expansion
by: Dorota A. Nawrot, et al.
Published: (2022-04-01)